20.23
-0.56 (-2.69%)
| Previous Close | 20.79 |
| Open | 20.93 |
| Volume | 274,642 |
| Avg. Volume (3M) | 383,680 |
| Market Cap | 957,769,088 |
| Price / Earnings (Forward) | 250.00 |
| Price / Sales | 10.55 |
| Price / Book | 3.89 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2024 - 12 Aug 2024 |
| Profit Margin | -31.32% |
| Operating Margin (TTM) | -5.10% |
| Diluted EPS (TTM) | -1.11 |
| Quarterly Revenue Growth (YOY) | 29.70% |
| Total Debt/Equity (MRQ) | 12.06% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | 9.10 M |
| Levered Free Cash Flow (TTM) | 10.14 M |
| Return on Assets (TTM) | -5.97% |
| Return on Equity (TTM) | -15.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | BioLife Solutions, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.63 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 1.94% |
| % Held by Institutions | 99.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Keybanc, 63.12%) | Buy |
| Median | 31.00 (53.24%) | |
| Low | 27.00 (HC Wainwright & Co., 33.47%) | Buy |
| Average | 30.60 (51.26%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 24.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 19 Dec 2024 | 30.00 (48.29%) | Buy | 26.11 |
| Keybanc | 13 Dec 2024 | 33.00 (63.12%) | Buy | 26.70 |
| HC Wainwright & Co. | 18 Nov 2024 | 27.00 (33.47%) | Buy | 20.47 |
| 30 Sep 2024 | 29.00 (43.35%) | Buy | 25.04 | |
| Craig-Hallum | 13 Nov 2024 | 32.00 (58.18%) | Buy | 24.11 |
| TD Cowen | 13 Nov 2024 | 31.00 (53.24%) | Buy | 24.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2024 | Announcement | BioLife Solutions Appoints Tony J. Hunt to its Board of Directors |
| 14 Nov 2024 | Announcement | BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary |
| 12 Nov 2024 | Announcement | BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary |
| 12 Nov 2024 | Announcement | BioLife Solutions Reports Third Quarter 2024 Financial Results |
| 31 Oct 2024 | Announcement | BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |